Allogene Therapeutics, Inc. (ALLO) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall St on pace for higher open as oil pulls back ahead of Fed decision
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mail
Get Alerts ALLO Hot Sheet
Join SI Premium – FREE
Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35).
For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cipher Digital rises as AI data center rebuttal lifts sector
- Applied Digital rises after insider stock pick recognition
- Alphabet (GOOG) call put ratio 2.8 calls to 1 put into quarter results
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
